HealthyPhase 1NCT06440980

A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight

A Phase 1 study testing Orforglipron in people with Healthy and Obese, run by Eli Lilly and Company at 7 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

The main purpose of this study is to see how much of orforglipron (study drug) gets into the bloodstream and how long it takes the body to get rid of it when given as capsules compared to tablets in healthy overweight and obese participants. Read more about this study

Who is it for?: Ages 18 to 65 yearsHealthy volunteers can take part
Conditions the study is for: Healthy, Obese, Overweight
What is being tested?: Orforglipron
Type of treatment: Pill or oral medicine
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 533 participants
Where: 7 sitesUnited States
Study dates: 24 Jun 2024to 2 Jun 2025
Phase: Phase 1
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 65 years
All sexes
Healthy volunteers accepted
Adult, Older adult

Who may be able to join

Participants who are overtly healthy as determined by medical history and physical examination.
Have a stable body weight for one month prior to screening (less than or equal to 5 percent body weight gain or loss) and Body Mass Index (BMI) in range of 27 to 40 kilogram per meter square (kg/m²).
Participants must be reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures.
Have venous access sufficient to allow for blood sampling.

Who cannot join

Have hemoglobin A1c (HbA1c) level of 6.5 percent (%) or greater.
Have a history of current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders or other significant active, uncontrolled medical conditions.
Have significant history of or currently have major depressive disorder or psychiatric disorder within the last 2 years.
Obesity induced by other endocrine disorders, such as Cushing's syndrome or Prader-Willi syndrome.
Have known clinically significant gastric emptying abnormality.
Have undergone bariatric surgery (for example: Lap-Band, Gastric Bypass)

Show all 11Show fewer

Have a known self or family history (first-degree relative) of multiple endocrine neoplasia type 2A or type 2B, thyroid C-cell hyperplasia, or any form of thyroid cancer.
Have an abnormal 12-lead electrocardiogram (ECG) at screening.
Have history of pancreatitis.
Judged by the study investigator to be at serious suicidal risk and have answered "Yes" to either question 4 or 5 on the Columbia-Suicide Severity Rating Scale [C-SSRS]).
Have difficulty swallowing capsules or tablets.

Trial locations and contacts

7 sites in 1 country.

City, postcode or hospital

7 sites in 1 country

United States7 sites

Anaheim Clinical Trials, LLC
Anaheim, California, 92801
Fortrea Clinical Research Unit
Dallas, Texas, 75247
Fortrea Clinical Research Unit
Daytona Beach, Florida, 32117
Collaborative Neuroscience Research, LLC
Los Alamitos, California, 90720
Fortrea Clinical Research Unit
Madison, Wisconsin, 53704
Altasciences Company Inc.
Overland Park, Kansas, 66212
QPS
Springfield, Missouri, 65802

Other trials in United States

About this study

Official title: A Multiple-Dose Study to Investigate the Bioequivalence of Orforglipron (LY3502970) Capsules and Orforglipron Tablets in Participants With Obesity or Overweight Who Are Otherwise Healthy.

The study will be conducted in two parts, with part A and B lasting up to approximately 25 and 22 weeks each respectively, including the screening period.

Conditions: Healthy, Obese, Overweight, Obesity
Being tested: Orforglipron
Keywords: Pharmacokinetics
Medical subject headings: Obesity, Overweight

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

OrforglipronDrug
Also called LY3502970
Administered orally

Study groups in NCT06440980
Study group	Role	What they receive
Part A: LY3502970 QD Oral Administration (Cohort 1A, Sequence 1)	Experimental	Participants received LY3502970 orally once daily (QD) across inpatient Treatment Periods 1-12 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows: * Period 1: 1 mg (Capsule) * Period 2: Dose Level 2 (Tablet) * Period 3: Dose Level 1 (Tablet) * Period 4: Dose Level 3 (Tablet) * Period 5: 3 mg (Capsule) * Period 6: Dose Level 5 (Tablet) * Period 7: Dose Level 4 (Tablet) * Period 8: Dose Level 6 (Tablet) * Period 9: 6 mg (Capsule) * Period 10: Dose Level 8 (Tablet) * Period 11: Dose Level 7 (Tablet) * Period 12: Dose Level 9 (Tablet) Receives: Drug: Orforglipron
Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 2)	Experimental	Participants received LY3502970 orally QD across inpatient Treatment Periods 1-12 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows: * Period 1: Dose Level 2 (Tablet) * Period 2: 1 mg (Capsule) * Period 3: Dose Level 3 (Tablet) * Period 4: Dose Level 1 (Tablet) * Period 5: Dose Level 5 (Tablet) * Period 6: 3 mg (Capsule) * Period 7: Dose Level 6 (Tablet) * Period 8: Dose Level 4 (Tablet) * Period 9: Dose Level 8 (Tablet) * Period 10: 6 mg (Capsule) * Period 11: Dose Level 9 (Tablet) * Period 12: Dose Level 7 (Tablet) Receives: Drug: Orforglipron
Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 3)	Experimental	Participants received LY3502970 orally QD across inpatient Treatment Periods 1-12 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows: * Period 1: Dose Level 1 (Tablet) * Period 2: Dose Level 3 (Tablet) * Period 3: 1 mg (Capsule) * Period 4: Dose Level 2 (Tablet) * Period 5: Dose Level 4 (Tablet) * Period 6: Dose Level 6 (Tablet) * Period 7: 3 mg (Capsule) * Period 8: Dose Level 5 (Tablet) * Period 9: Dose Level 7 (Tablet) * Period 10: Dose Level 9 (Tablet) * Period 11: 6 mg (Capsule) * Period 12: Dose Level 8 (Tablet) Receives: Drug: Orforglipron
Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 4)	Experimental	Participants received LY3502970 orally QD across inpatient Treatment Periods 1-12 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows: * Period 1: Dose Level 3 (Tablet) * Period 2: Dose Level 1 (Tablet) * Period 3: Dose Level 2 (Tablet) * Period 4: 1 mg (Capsule) * Period 5: Dose Level 6 (Tablet) * Period 6: Dose Level 4 (Tablet) * Period 7: Dose Level 5 (Tablet) * Period 8: 3 mg (Capsule) * Period 9: Dose Level 9 (Tablet) * Period 10: Dose Level 7 (Tablet) * Period 11: Dose Level 8 (Tablet) * Period 12: 6 mg (Capsule) Receives: Drug: Orforglipron
Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 1)	Experimental	Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg and 6 mg; Capsule), followed by inpatient Treatment Periods 7-18 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows: * Period 7: 12 mg (Capsule) * Period 8: Dose Level 11 (Tablet) * Period 9: Dose Level 10 (Tablet) * Period 10: Dose Level 12 (Tablet) * Period 11: 24 mg (Capsule) * Period 12: Dose Level 14 (Tablet) * Period 13: Dose Level 13 (Tablet) * Period 14: Dose Level 16 (Tablet) * Period 15: 36 mg (Capsule) * Period 16: Dose Level 17 (Tablet) * Period 17: Dose Level 15 (Tablet) * Period 18: Dose Level 18 (Tablet) Receives: Drug: Orforglipron
Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 2)	Experimental	Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg, and 6 mg; Capsule), followed by inpatient Treatment Periods 7-18 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows: * Period 7: Dose Level 11 (Tablet) * Period 8: 12 mg (Capsule) * Period 9: Dose Level 12 (Tablet) * Period 10: Dose Level 10 (Tablet) * Period 11: Dose Level 14 (Tablet) * Period 12: 24 mg (Capsule) * Period 13: Dose Level 16 (Tablet) * Period 14: Dose Level 13 (Tablet) * Period 15: Dose Level 17 (Tablet) * Period 16: 36 mg (Capsule) * Period 17: Dose Level 18 (Tablet) * Period 18: Dose Level 15 (Tablet) Receives: Drug: Orforglipron
Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 3)	Experimental	Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg and 6 mg; Capsule), followed by inpatient Treatment Periods 7-18 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows: * Period 7: Dose Level 10 (Tablet) * Period 8: Dose Level 12 (Tablet) * Period 9: 12 mg (Capsule) * Period 10: Dose Level 11 (Tablet) * Period 11: Dose Level 13 (Tablet) * Period 12: Dose Level 16 (Tablet) * Period 13: 24 mg (Capsule) * Period 14: Dose Level 14 (Tablet) * Period 15: Dose Level 15 (Tablet) * Period 16: Dose Level 18 (Tablet) * Period 17: 36 mg (Capsule) * Period 18: Dose Level 17 (Tablet) Receives: Drug: Orforglipron
Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 4)	Experimental	Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg, and 6 mg; Capsule), followed by inpatient Treatment Periods 7-18 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows: * Period 7: Dose Level 12 (Tablet) * Period 8: Dose Level 10 (Tablet) * Period 9: Dose Level 11 (Tablet) * Period 10: 12 mg (Capsule) * Period 11: Dose Level 16 (Tablet) * Period 12: Dose Level 13 (Tablet) * Period 13: Dose Level 14 (Tablet) * Period 14: 24 mg (Capsule) * Period 15: Dose Level 18 (Tablet) * Period 16: Dose Level 15 (Tablet) * Period 17: Dose Level 17 (Tablet) * Period 18: 36 mg (Capsule) Receives: Drug: Orforglipron
Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 1)	Experimental	Participants received LY3502970 orally QD across inpatient Treatment Periods 1-9 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows: * Period 1: 1 mg (Capsule- First Treatment) * Period 2: 1 mg (Capsule- Second Treatment) * Period 3: 0.8 mg (Tablet) * Period 4: 3 mg (Capsule- First Treatment) * Period 5: 3 mg (Capsule- Second Treatment) * Period 6: 2.5 mg (Tablet) * Period 7: 6 mg (Capsule- First Treatment) * Period 8: 6 mg (Capsule- Second Treatment) * Period 9: 5.5 mg (Tablet) Receives: Drug: Orforglipron
Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 2)	Experimental	Participants received LY3502970 orally QD across inpatient Treatment Periods 1-9 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows: * Period 1: 1 mg (Capsule- First Treatment) * Period 2: 0.8 mg (Tablet) * Period 3: 1 mg (Capsule- Second Treatment) * Period 4: 3 mg (Capsule- First Treatment) * Period 5: 2.5 mg (Tablet) * Period 6: 3 mg (Capsule- Second Treatment) * Period 7: 6 mg (Capsule- First Treatment) * Period 8: 5.5 mg (Tablet) * Period 9: 6 mg (Capsule- Second Treatment) Receives: Drug: Orforglipron
Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 3)	Experimental	Participants received LY3502970 orally QD across inpatient Treatment Periods 1-9 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows: * Period 1: 0.8 mg (Tablet) * Period 2: 1 mg (Capsule- First Treatment) * Period 3: 1 mg (Capsule- Second Treatment) * Period 4: 2.5 mg (Tablet) * Period 5: 3 mg (Capsule- First Treatment) * Period 6: 3 mg (Capsule- Second Treatment) * Period 7: 5.5 mg (Tablet) * Period 8: 6 mg (Capsule- First Treatment) * Period 9: 6 mg (Capsule- Second Treatment) Receives: Drug: Orforglipron
Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 1)	Experimental	Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg, and 6 mg [Capsule]), followed by inpatient Treatment Periods 7-15 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows: * Period 7: 12 mg (Capsule- First Treatment) * Period 8: 12 mg (Capsule- Second Treatment) * Period 9: 9 mg (Tablet) * Period 10: 24 mg (Capsule- First Treatment) * Period 11: 24 mg (Capsule- Second Treatment) * Period 12: 14.5 mg (Tablet) * Period 13: 36 mg (Capsule- First Treatment) * Period 14: 36 mg (Capsule- Second Treatment) * Period 15: 17.2 mg (Tablet) Receives: Drug: Orforglipron
Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 2)	Experimental	Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg, and 6 mg [Capsule]), followed by inpatient Treatment Periods 7-15 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows: * Period 7: 12 mg (Capsule- First Treatment) * Period 8: 9 mg (Tablet) * Period 9: 12 mg (Capsule- Second Treatment) * Period 10: 24 mg (Capsule- First Treatment) * Period 11: 14.5 mg (Tablet) * Period 12: 24 mg (Capsule- Second Treatment) * Period 13: 36 mg (Capsule- First Treatment) * Period 14: 17.2 mg (Tablet) * Period 15: 36 mg (Capsule- Second Treatment) Receives: Drug: Orforglipron
Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 3)	Experimental	Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg, and 6 mg [Capsule]), followed by inpatient Treatment Periods 7-15 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows: * Period 7: 9 mg (Tablet) * Period 8: 12 mg (Capsule- First Treatment) * Period 9: 12 mg (Capsule- Second Treatment) * Period 10: 14.5 mg (Tablet) * Period 11: 24 mg (Capsule- First Treatment) * Period 12: 24 mg (Capsule- Second Treatment) * Period 13: 17.2 mg (Tablet) * Period 14: 36 mg (Capsule- First Treatment) * Period 15: 36 mg (Capsule- Second Treatment) Receives: Drug: Orforglipron

What is being measured

The primary outcome is the main question the study is designed to answer.

Part B: Pharmacokinetics (PK): Steady-state Area Under the Concentration Time Curve From Time Zero to the End of the Dosing Interval, Tau (AUC[0-tau]) of LY3502970 on Day 7
PK: Area under the concentration versus time curve from time 0 to the end of the once daily dosing interval at steady state AUC[0-tau] on Day 7.
Measured: Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose on Day 7 for each dosing treatment period (1 period=7 days)
Part B: PK: Steady-state Maximum Observed Concentration (Cmax) of LY3502970 on Day 7
PK: Maximum concentration of LY3502970 during a once daily dosing interval at steady state on Day 7.
Measured: Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose on Day 7 for each dosing treatment period (1 period=7 days)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

24 Jun 20242 Jun 2025

First posted4 Jun 2024
Study start24 Jun 2024
Primary completion2 Jun 2025
Study completion2 Jun 2025

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Publications (1)Papers the sponsor has linked to this study.
Other trials for HealthyStudies of the same condition, open and under way.
More trials run by Eli Lilly and CompanyThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 1
Primary purpose: Basic science
Allocation: Randomised
Intervention model: Parallel groups
Masking: None (open label)
Enrolment: 533 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT06440980
Sponsor's protocol ID: 18617
Other IDs: J2A-MC-GZPI
Status last verified: Jun 2026
First submitted: 29 May 2024
Last updated: 17 Jul 2026
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: No
FDA-regulated drug: Yes
FDA-regulated device: No
Individual data sharing: No

Publications

Ma X, Li YG, Raha S, Sperry DC, Coutant DE, Bhattachar S. Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight. Diabetes Obes Metab. 2026 Jul;28(7):5803-5809. doi: 10.1111/dom.70783. Epub 2026 Apr 17.
PubMed 41994902

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis

All Healthy trials

Study at a glance

From the registry record, last updated by the sponsor on 17 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Multiple-Dose Study to Investigate the Bioequivalence of Orforglipron (LY3502970) Capsules and Orforglipron Tablets in Participants With Obesity or Overweight Who Are Otherwise Healthy.
ClinicalTrials.gov ID: NCT06440980
Acronym / sponsor ID: 18617
Conditions: Healthy, Obese, Overweight, Obesity
Keywords: Pharmacokinetics
Phase: Phase 1
Study type: Interventional
Recruitment status: Completed
Enrolment: 533 participants (actual)
Lead sponsor: Eli Lilly and CompanyIndustry (pharma, biotech, devices)
Study start: 24 Jun 2024 (actual)
Primary completion: 2 Jun 2025 (actual)
Study completion: 2 Jun 2025 (actual)
First posted: 4 Jun 2024 (actual)
Results: Posted 17 Jul 2026

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

The study will be conducted in two parts, with part A and B lasting up to approximately 25 and 22 weeks each respectively, including the screening period.

Study design

Primary purpose: Basic science
Allocation: Randomised
Intervention model: Parallel groups
Masking: None (open label)
Number of arms: 14

Arm	Type	Receives
Part A: LY3502970 QD Oral Administration (Cohort 1A, Sequence 1)	Experimental	Drug: OrforglipronParticipants received LY3502970 orally once daily (QD) across inpatient Treatment Periods 1-12 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows: * Period 1: 1 mg (Capsule) * Period 2: Dose Level 2 (Tablet) * Period 3: Dose Level 1 (Tablet) * Period 4: Dose Level 3 (Tablet) * Period 5: 3 mg (Capsule) * Period 6: Dose Level 5 (Tablet) * Period 7: Dose Level 4 (Tablet) * Period 8: Dose Level 6 (Tablet) * Period 9: 6 mg (Capsule) * Period 10: Dose Level 8 (Tablet) * Period 11: Dose Level 7 (Tablet) * Period 12: Dose Level 9 (Tablet)
Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 2)	Experimental	Drug: OrforglipronParticipants received LY3502970 orally QD across inpatient Treatment Periods 1-12 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows: * Period 1: Dose Level 2 (Tablet) * Period 2: 1 mg (Capsule) * Period 3: Dose Level 3 (Tablet) * Period 4: Dose Level 1 (Tablet) * Period 5: Dose Level 5 (Tablet) * Period 6: 3 mg (Capsule) * Period 7: Dose Level 6 (Tablet) * Period 8: Dose Level 4 (Tablet) * Period 9: Dose Level 8 (Tablet) * Period 10: 6 mg (Capsule) * Period 11: Dose Level 9 (Tablet) * Period 12: Dose Level 7 (Tablet)
Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 3)	Experimental	Drug: OrforglipronParticipants received LY3502970 orally QD across inpatient Treatment Periods 1-12 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows: * Period 1: Dose Level 1 (Tablet) * Period 2: Dose Level 3 (Tablet) * Period 3: 1 mg (Capsule) * Period 4: Dose Level 2 (Tablet) * Period 5: Dose Level 4 (Tablet) * Period 6: Dose Level 6 (Tablet) * Period 7: 3 mg (Capsule) * Period 8: Dose Level 5 (Tablet) * Period 9: Dose Level 7 (Tablet) * Period 10: Dose Level 9 (Tablet) * Period 11: 6 mg (Capsule) * Period 12: Dose Level 8 (Tablet)
Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 4)	Experimental	Drug: OrforglipronParticipants received LY3502970 orally QD across inpatient Treatment Periods 1-12 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows: * Period 1: Dose Level 3 (Tablet) * Period 2: Dose Level 1 (Tablet) * Period 3: Dose Level 2 (Tablet) * Period 4: 1 mg (Capsule) * Period 5: Dose Level 6 (Tablet) * Period 6: Dose Level 4 (Tablet) * Period 7: Dose Level 5 (Tablet) * Period 8: 3 mg (Capsule) * Period 9: Dose Level 9 (Tablet) * Period 10: Dose Level 7 (Tablet) * Period 11: Dose Level 8 (Tablet) * Period 12: 6 mg (Capsule)
Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 1)	Experimental	Drug: OrforglipronParticipants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg and 6 mg; Capsule), followed by inpatient Treatment Periods 7-18 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows: * Period 7: 12 mg (Capsule) * Period 8: Dose Level 11 (Tablet) * Period 9: Dose Level 10 (Tablet) * Period 10: Dose Level 12 (Tablet) * Period 11: 24 mg (Capsule) * Period 12: Dose Level 14 (Tablet) * Period 13: Dose Level 13 (Tablet) * Period 14: Dose Level 16 (Tablet) * Period 15: 36 mg (Capsule) * Period 16: Dose Level 17 (Tablet) * Period 17: Dose Level 15 (Tablet) * Period 18: Dose Level 18 (Tablet)
Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 2)	Experimental	Drug: OrforglipronParticipants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg, and 6 mg; Capsule), followed by inpatient Treatment Periods 7-18 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows: * Period 7: Dose Level 11 (Tablet) * Period 8: 12 mg (Capsule) * Period 9: Dose Level 12 (Tablet) * Period 10: Dose Level 10 (Tablet) * Period 11: Dose Level 14 (Tablet) * Period 12: 24 mg (Capsule) * Period 13: Dose Level 16 (Tablet) * Period 14: Dose Level 13 (Tablet) * Period 15: Dose Level 17 (Tablet) * Period 16: 36 mg (Capsule) * Period 17: Dose Level 18 (Tablet) * Period 18: Dose Level 15 (Tablet)
Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 3)	Experimental	Drug: OrforglipronParticipants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg and 6 mg; Capsule), followed by inpatient Treatment Periods 7-18 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows: * Period 7: Dose Level 10 (Tablet) * Period 8: Dose Level 12 (Tablet) * Period 9: 12 mg (Capsule) * Period 10: Dose Level 11 (Tablet) * Period 11: Dose Level 13 (Tablet) * Period 12: Dose Level 16 (Tablet) * Period 13: 24 mg (Capsule) * Period 14: Dose Level 14 (Tablet) * Period 15: Dose Level 15 (Tablet) * Period 16: Dose Level 18 (Tablet) * Period 17: 36 mg (Capsule) * Period 18: Dose Level 17 (Tablet)
Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 4)	Experimental	Drug: OrforglipronParticipants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg, and 6 mg; Capsule), followed by inpatient Treatment Periods 7-18 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows: * Period 7: Dose Level 12 (Tablet) * Period 8: Dose Level 10 (Tablet) * Period 9: Dose Level 11 (Tablet) * Period 10: 12 mg (Capsule) * Period 11: Dose Level 16 (Tablet) * Period 12: Dose Level 13 (Tablet) * Period 13: Dose Level 14 (Tablet) * Period 14: 24 mg (Capsule) * Period 15: Dose Level 18 (Tablet) * Period 16: Dose Level 15 (Tablet) * Period 17: Dose Level 17 (Tablet) * Period 18: 36 mg (Capsule)
Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 1)	Experimental	Drug: OrforglipronParticipants received LY3502970 orally QD across inpatient Treatment Periods 1-9 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows: * Period 1: 1 mg (Capsule- First Treatment) * Period 2: 1 mg (Capsule- Second Treatment) * Period 3: 0.8 mg (Tablet) * Period 4: 3 mg (Capsule- First Treatment) * Period 5: 3 mg (Capsule- Second Treatment) * Period 6: 2.5 mg (Tablet) * Period 7: 6 mg (Capsule- First Treatment) * Period 8: 6 mg (Capsule- Second Treatment) * Period 9: 5.5 mg (Tablet)
Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 2)	Experimental	Drug: OrforglipronParticipants received LY3502970 orally QD across inpatient Treatment Periods 1-9 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows: * Period 1: 1 mg (Capsule- First Treatment) * Period 2: 0.8 mg (Tablet) * Period 3: 1 mg (Capsule- Second Treatment) * Period 4: 3 mg (Capsule- First Treatment) * Period 5: 2.5 mg (Tablet) * Period 6: 3 mg (Capsule- Second Treatment) * Period 7: 6 mg (Capsule- First Treatment) * Period 8: 5.5 mg (Tablet) * Period 9: 6 mg (Capsule- Second Treatment)
Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 3)	Experimental	Drug: OrforglipronParticipants received LY3502970 orally QD across inpatient Treatment Periods 1-9 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows: * Period 1: 0.8 mg (Tablet) * Period 2: 1 mg (Capsule- First Treatment) * Period 3: 1 mg (Capsule- Second Treatment) * Period 4: 2.5 mg (Tablet) * Period 5: 3 mg (Capsule- First Treatment) * Period 6: 3 mg (Capsule- Second Treatment) * Period 7: 5.5 mg (Tablet) * Period 8: 6 mg (Capsule- First Treatment) * Period 9: 6 mg (Capsule- Second Treatment)
Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 1)	Experimental	Drug: OrforglipronParticipants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg, and 6 mg [Capsule]), followed by inpatient Treatment Periods 7-15 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows: * Period 7: 12 mg (Capsule- First Treatment) * Period 8: 12 mg (Capsule- Second Treatment) * Period 9: 9 mg (Tablet) * Period 10: 24 mg (Capsule- First Treatment) * Period 11: 24 mg (Capsule- Second Treatment) * Period 12: 14.5 mg (Tablet) * Period 13: 36 mg (Capsule- First Treatment) * Period 14: 36 mg (Capsule- Second Treatment) * Period 15: 17.2 mg (Tablet)
Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 2)	Experimental	Drug: OrforglipronParticipants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg, and 6 mg [Capsule]), followed by inpatient Treatment Periods 7-15 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows: * Period 7: 12 mg (Capsule- First Treatment) * Period 8: 9 mg (Tablet) * Period 9: 12 mg (Capsule- Second Treatment) * Period 10: 24 mg (Capsule- First Treatment) * Period 11: 14.5 mg (Tablet) * Period 12: 24 mg (Capsule- Second Treatment) * Period 13: 36 mg (Capsule- First Treatment) * Period 14: 17.2 mg (Tablet) * Period 15: 36 mg (Capsule- Second Treatment)
Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 3)	Experimental	Drug: OrforglipronParticipants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg, and 6 mg [Capsule]), followed by inpatient Treatment Periods 7-15 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows: * Period 7: 9 mg (Tablet) * Period 8: 12 mg (Capsule- First Treatment) * Period 9: 12 mg (Capsule- Second Treatment) * Period 10: 14.5 mg (Tablet) * Period 11: 24 mg (Capsule- First Treatment) * Period 12: 24 mg (Capsule- Second Treatment) * Period 13: 17.2 mg (Tablet) * Period 14: 36 mg (Capsule- First Treatment) * Period 15: 36 mg (Capsule- Second Treatment)

Who may qualify

Ages: 18 to 65 years
Sex: All
Healthy volunteers: Accepted
Age groups: Adult, Older adult

Key inclusion criteria (4 listed)

Participants who are overtly healthy as determined by medical history and physical examination.
Have a stable body weight for one month prior to screening (less than or equal to 5 percent body weight gain or loss) and Body Mass Index (BMI) in range of 27 to 40 kilogram per meter square (kg/m²).
Participants must be reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures.
Have venous access sufficient to allow for blood sampling.

Key exclusion criteria (11 listed)

Have hemoglobin A1c (HbA1c) level of 6.5 percent (%) or greater.
Have a history of current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders or other significant active, uncontrolled medical conditions.
Have significant history of or currently have major depressive disorder or psychiatric disorder within the last 2 years.
Obesity induced by other endocrine disorders, such as Cushing's syndrome or Prader-Willi syndrome.
Have known clinically significant gastric emptying abnormality.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
OrforglipronAlso: LY3502970Administered orally	Drug	Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 2), Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 3), Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 4), Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 1), Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 2), Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 3), Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 4), Part A: LY3502970 QD Oral Administration (Cohort 1A, Sequence 1), Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 1), Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 2), Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 3), Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 1), Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 2), Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 3)

Primary outcome

Part B: Pharmacokinetics (PK): Steady-state Area Under the Concentration Time Curve From Time Zero to the End of the Dosing Interval, Tau (AUC[0-tau]) of LY3502970 on Day 7
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose on Day 7 for each dosing treatment period (1 period=7 days)
PK: Area under the concentration versus time curve from time 0 to the end of the once daily dosing interval at steady state AUC[0-tau] on Day 7.
Part B: PK: Steady-state Maximum Observed Concentration (Cmax) of LY3502970 on Day 7
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose on Day 7 for each dosing treatment period (1 period=7 days)
PK: Maximum concentration of LY3502970 during a once daily dosing interval at steady state on Day 7.

Results and safety

Results posted to the registry on 17 Jul 2026, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Part A: LY3502970 QD Oral Administration (Cohort 1A, Sequence 1)	13	13
Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 2)	13	12
Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 3)	13	10
Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 4)	13	10
Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 1)	0	0
Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 2)	0	0
Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 3)	0	0
Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 4)	0	0
Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 1)	0	0
Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 2)	0	0
Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 3)	0	0
Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 1)	0	0
Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 2)	0	0
Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 3)	0	0

Primary outcome: Part B: Pharmacokinetics (PK): Steady-state Area Under the Concentration Time Curve From Time Zero to the End of the Dosing Interval, Tau (AUC[0-tau]) of LY3502970 on Day 7

Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose on Day 7 for each dosing treatment period (1 period=7 days). Geometric mean (Geometric Coefficient of Variation). Unit: Nanogram* hours/milliliter (ng*h/ml)

Measure	Cohort 1B: 1 mg LY3502970 Capsule QD (First Treatment) n = 213	Cohort 1B: 1 mg LY3502970 Capsule QD (Second Treatment) n = 210	Cohort 1B: 0.8 mg LY3502970 Tablet QD n = 211	Cohort 1B: 3 mg LY3502970 Capsule QD (First Treatment) n = 205	Cohort 1B: 3 mg LY3502970 Capsule QD (Second Treatment) n = 204	Cohort 1B: 2.5 mg LY3502970 Tablet QD n = 207	Cohort 1B: 6 mg LY3502970 Capsule QD (First Treatment) n = 196	Cohort 1B: 6 mg LY3502970 Capsule QD (Second Treatment) n = 196	Cohort 1B: 5.5 mg LY3502970 Tablet QD n = 199	Cohort 2B: 12 mg LY3502970 Capsule QD (First Treatment) n = 176	Cohort 2B: 12 mg LY3502970 Capsule QD (Second Treatment) n = 179	Cohort 2B: 9 mg LY3502970 Tablet QD n = 182	Cohort 2B: 24 mg LY3502970 Capsule QD (First Treatment) n = 175	Cohort 2B: 24 mg LY3502970 Capsule QD (Second Treatment) n = 177	Cohort 2B: 14.5 mg LY3502970 Tablet QD n = 179	Cohort 2B: 36 mg LY3502970 Capsule QD (First Treatment) n = 173	Cohort 2B: 36 mg LY3502970 Capsule QD (Second Treatment) n = 170	Cohort 2B: 17.2 mg LY3502970 Tablet QD n = 173
Value	80.2 (37.8)	82.1 (39.7)	78.9 (36.6)	240 (38.8)	252 (39.1)	247 (37.3)	517 (47.4)	541 (60.4)	524 (45.4)	829 (46.4)	841 (46.3)	790 (40.3)	1210 (50.0)	1260 (57.5)	1200 (64.2)	1500 (71.5)	1500 (71.9)	1520 (60.4)

Population analysed: The PK population included all enrolled participants who received at least one dose of study drug and had evaluable pharmacokinetic data for this specific outcome measure. As pre-specified in the statistical analysis plan, only participants with valid data from all three treatment periods (two capsule treatment and one tablet treatment) corresponding to the relevant dose level were included in the analysis.

Primary outcome: Part B: PK: Steady-state Maximum Observed Concentration (Cmax) of LY3502970 on Day 7

Measure	Cohort 1B: 1 mg LY3502970 Capsule QD (First Treatment) n = 213	Cohort 1B: 1 mg LY3502970 Capsule QD (Second Treatment) n = 210	Cohort 1B: 0.8 mg LY3502970 Tablet QD n = 211	Cohort 1B: 3 mg LY3502970 Capsule QD (First Treatment) n = 205	Cohort 1B: 3 mg LY3502970 Capsule QD (Second Treatment) n = 204	Cohort 1B: 2.5 mg LY3502970 Tablet QD n = 207	Cohort 1B: 6 mg LY3502970 Capsule QD (First Treatment) n = 196	Cohort 1B: 6 mg LY3502970 Capsule QD (Second Treatment) n = 196	Cohort 1B: 5.5 mg LY3502970 Tablet QD n = 200	Cohort 2B: 12 mg LY3502970 Capsule QD (First Treatment) n = 177	Cohort 2B: 12 mg LY3502970 Capsule QD (Second Treatment) n = 179	Cohort 2B: 9 mg LY3502970 Tablet QD n = 182	Cohort 2B: 24 mg LY3502970 Capsule QD (First Treatment) n = 175	Cohort 2B: 24 mg LY3502970 Capsule QD (Second Treatment) n = 177	Cohort 2B: 14.5 mg LY3502970 Tablet QD n = 179	Cohort 2B: 36 mg LY3502970 Capsule QD (First Treatment) n = 173	Cohort 2B: 36 mg LY3502970 Capsule QD (Second Treatment) n = 170	Cohort 2B: 17.2 mg LY3502970 Tablet QD n = 173
Value	5.39 (37.9)	5.60 (39.5)	5.38 (35.9)	16.2 (41.2)	16.8 (38.8)	16.8 (37.4)	35.1 (50.0)	36.8 (63.6)	34.9 (63.9)	55.0 (55.0)	55.6 (51.3)	53.5 (41.7)	80.0 (52.1)

Adverse events

Time frame: Cohort 1A: Baseline Up to end of follow up (Up to 13 weeks); Cohort 2A: Baseline Up to end of follow up (Up to 19 weeks); Cohort 1B: Baseline Up to end of follow up (Up to 10 weeks); Cohort 2B: Baseline Up to end of follow up (Up to 16 weeks).. Other adverse events reported at 5% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Cohort 1A: 1 mg LY3502970 Capsule QD	0 of 52 (0%)	6 of 52 (11.5%)	0 of 52
Cohort 1A: LY3502970 Tablet QD (Dose Level 1)	0 of 52 (0%)	8 of 52 (15.4%)	0 of 52
Cohort 1A: LY3502970 Tablet QD (Dose Level 2)	0 of 52 (0%)	7 of 52 (13.5%)	0 of 52
Cohort 1A: LY3502970 Tablet QD (Dose Level 3)	0 of 52 (0%)	9 of 52 (17.3%)	0 of 52
Cohort 1A: 3 mg LY3502970 Capsule QD	0 of 47 (0%)	6 of 47 (12.8%)	0 of 47
Cohort 1A: LY3502970 Tablet QD (Dose Level 4)	0 of 51 (0%)	9 of 51 (17.6%)	0 of 51
Cohort 1A: LY3502970 Tablet QD (Dose Level 5)	0 of 48 (0%)	10 of 48 (20.8%)	0 of 48
Cohort 1A: LY3502970 Tablet QD (Dose Level 6)	0 of 51 (0%)	13 of 51 (25.5%)	0 of 51
Cohort 1A: 6 mg LY3502970 Capsule QD	0 of 46 (0%)	7 of 46 (15.2%)	0 of 46
Cohort 1A: LY3502970 Tablet QD (Dose Level 7)	0 of 46 (0%)	6 of 46 (13%)	0 of 46
Cohort 1A: LY3502970 Tablet QD (Dose Level 8)	0 of 47 (0%)	7 of 47 (14.9%)	0 of 47
Cohort 1A: LY3502970 Tablet QD (Dose Level 9)	0 of 46 (0%)	10 of 46 (21.7%)	0 of 46
Cohort 2A: 1/3/6 mg LY3502970 Capsule QD (Home Dosing)	0 of 52 (0%)	11 of 52 (21.2%)	0 of 52
Cohort 2A: 12 mg LY3502970 Capsule QD	0 of 50 (0%)	7 of 50 (14%)	0 of 50
Cohort 2A: LY3502970 Tablet QD (Dose Level 10)	0 of 50 (0%)	16 of 50 (32%)	0 of 50
Cohort 2A:LY3502970 Tablet QD (Dose Level 11)	0 of 50 (0%)

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 17 Jul 2026.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Derived from this study: PubMed 41994902Ma X, Li YG, Raha S, Sperry DC, Coutant DE, Bhattachar S. Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight. Diabetes Obes Metab. 2026 Jul;28(7):5803-5809. doi: 10.1111/dom.70783. Epub 2026 Apr 17.
A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or OverweightLink provided by the sponsor.
Individual participant dataSharing planned: No

Related trials for Healthy

Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) study director

Eli Lilly and Company

7 sites in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Orforglipron in people with Healthy and Obese, run by Eli Lilly and Company at 7 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 17 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 7 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 17 Jul 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Part B: Pharmacokinetics (PK): Steady-state Area Under the Concentration Time Curve From Time Zero to the End of the Dosing Interval, Tau (AUC[0-tau]) of LY3502970 on Day 7 (time frame: Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose on Day 7 for each dosing treatment period (1 period=7 days)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06440980, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jul 2026.